Rapid Cycling Bipolar Disorder Another niche indication?

Introduction

Rapid cycling bipolar disorder (RCBD) is a market with many unmet needs, although barriers to entry are high. Pharmaceutical manufacturers need to invest substantial money into clinical trials to show a drug’s efficacy, although at first glance, a low diagnosed population and poorly defined treatment strategy offers intangible returns. 

Scope

Epidemiology of RCBD, including prevalence and diagnosis rates 

Analysis of current drug treatment, which includes mood stabilizers, antidepressants, and antipsychotics 

Identification of unmet market needs 

Datamonitor’s strategic recommendations 

Report Highlights

Datamonitor believes combination therapy is the future of RCBD management. The recommended approach is for add-on rather than initial co-therapy. However, improved, better defined, and standardized treatment guidelines should be published. 

The treatment strategy for rapid cycling bipolar is major barrier to the quality of treatment. Datamonitor believes that this is not due to a lack of efficacious drugs, but that low levels of research into drug combinations has resulted in an unclear treatment strategy. 

Reasons to Purchase

Identify current treatment options and unmet needs in the market 

Assess market opportunities and potential, and the barriers to market entry 

Understand the role of government in defining treatment strategies 

Publisher: Datamonitor CNS Central Nervous System Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS.html#a91